undamentalytics Newsletter
Sign in

Neogenomics Inc key statistics and ratios

In fiscal 2025, Neogenomics Inc had return on equity of -12.4% and a net margin of -14.9%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Net margin−2.6%−0.2%1.0%2.0%0.9%−1.7%−28.3%−14.9%−11.9%−14.9%−4.1%
Return on equity−3.8%−0.2%1.1%1.9%0.7%−0.9%−13.7%−9.1%−8.5%−12.4%−3.9%
Return on assets−1.8%−0.1%0.6%1.3%0.5%−0.6%−8.0%−5.1%−4.7%−7.2%−2.4%
Effective tax rate——31.0%————————
R&D as % of revenue2.0%1.5%1.1%2.1%1.9%4.5%5.9%4.6%4.7%5.1%5.0%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 7 checks passed · September 30, 2026
What it owns · $1.4bn
Short-term assets $410mLonger-term assets $967m
What it owes, and who funded it · $1.4bn
Short-term liabilities $116mLonger-term liabilities $460mShareholders' equity $801m
  • Short-term assets cover short-term liabilities $410m of assets due within a year against $116m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $410m short-term assets against $460m of longer-dated liabilities.
  • More cash than debt $139m of cash against $375m of debt.
  • Debt below 40% of shareholders' equity Debt is 47% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 50% to 47% over five years.
  • A year's operating cash flow covers at least 20% of debt $4m of operating cash flow against $375m of debt.
  • Operating profit covers interest at least five times over Operating income of −$49m against $3m of interest.

From Neogenomics Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

34 /100

Weak moat

How hard Neogenomics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -3.6% of total assets over 10 years.

  • Pricing power 14 / 20

    Gross margin has been a median 43.5%, moving by 3.4 percentage points (standard deviation) across 9 years.

  • Durability 10 / 20

    Operating margin has been a median -14.3%; its worst year was -34.8%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 2 of 9 years, at a median -3.6% of revenue.

  • Discipline 13 / 20

    The diluted share count rose 6.5% over five years; stock-based pay has been a median 3.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (39 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: NEO vs RGENNEO vs TXGAZTA vs NEONEO vs TECH

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Neogenomics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neogenomics Inc.